Jefferies Financial Group Inc. Makes New Investment in Disc Medicine, Inc. $IRON

Jefferies Financial Group Inc. purchased a new stake in shares of Disc Medicine, Inc. (NASDAQ:IRON – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund purchased 10,795 shares of the company’s stock, valued at approximately $707,000.

Several other large investors have also recently bought and sold shares of IRON. State of Wyoming purchased a new stake in Disc Medicine in the 2nd quarter worth about $25,000. Allworth Financial LP purchased a new position in Disc Medicine during the 2nd quarter valued at about $46,000. Sterling Capital Management LLC grew its stake in Disc Medicine by 842.4% during the 3rd quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock valued at $61,000 after acquiring an additional 834 shares in the last quarter. Nykredit A S purchased a new position in Disc Medicine during the 2nd quarter valued at about $103,000. Finally, Pinnacle Wealth Planning Services Inc. purchased a new position in Disc Medicine during the 3rd quarter valued at about $119,000. 83.70% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of brokerages have recently weighed in on IRON. Morgan Stanley upped their target price on Disc Medicine from $90.00 to $92.00 and gave the company an “overweight” rating in a report on Tuesday, October 20th. BMO Capital Markets raised their price target on shares of Disc Medicine from $100.00 to $120.00 and gave the stock an “outperform” rating in a report on Monday, October 19th. Wall Street Zen raised shares of Disc Medicine from a “sell” rating to a “hold” rating in a research report on Saturday, November 7th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Disc Medicine in a research report on Thursday, October 15th. Finally, Guggenheim began coverage on shares of Disc Medicine in a research note on Monday, November 9th. They issued a “buy” rating and a $132.00 price objective on the stock. Twelve equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $124.18.

Check Out Our Latest Stock Report on Disc Medicine

Insider Buying and Selling at Disc Medicine

In related news, Director Kevin Bitterman sold 25,519 shares of Disc Medicine stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $80.23, for a total transaction of $2,047,389.37. Following the sale, the director directly owned 12,991 shares of the company’s stock, valued at $1,042,267.93. This trade represents a 66.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider William Savage sold 16,035 shares of the firm’s stock in a transaction that occurred on Tuesday, November 10th. The stock was sold at an average price of $85.09, for a total value of $1,364,418.15. Following the completion of the sale, the insider owned 63,445 shares of the company’s stock, valued at $5,398,535.05. This represents a 20.17% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 150,277 shares of company stock valued at $11,877,059 in the last ninety days. Company insiders own 3.76% of the company’s stock.

Disc Medicine Price Performance

NASDAQ IRON opened at $80.00 on Monday. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The stock’s 50-day moving average is $71.60 and its two-hundred day moving average is $71.07. The firm has a market cap of $3.64 billion, a P/E ratio of -12.62 and a beta of 0.96. The company has a debt-to-equity ratio of 0.10, a current ratio of 20.30 and a quick ratio of 20.30.

Disc Medicine (NASDAQ:IRON – Get Free Report) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.53) EPS for the quarter, beating the consensus estimate of ($1.63) by $0.10. On average, analysts anticipate that Disc Medicine, Inc. will post -6.20 earnings per share for the current fiscal year.

Disc Medicine Company Profile

(Free Report)

Disc Medicine, Inc. is a clinical-stage biopharmaceutical company developing treatments for serious hematologic diseases. Its research focuses on disorders involving heme production and iron regulation, biological processes that affect red blood cell function. The company’s development pipeline includes bitopertin, an investigational treatment for erythropoietic protoporphyria and X-linked protoporphyria, and DISC-0974, an investigational therapy being studied for anemia associated with myelofibrosis and chronic kidney disease.

Further Reading

Institutional Ownership by Quarter for Disc Medicine (NASDAQ:IRON)

Receive News & Ratings for Disc Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Disc Medicine and related companies with MarketBeat.com's FREE daily email newsletter.